Bengaluru April 20, 2026 : MicrobioTx today announced the launch of its Irritable Bowel Syndrome Risk Score a predictive solution that evaluates an individual’s likelihood of developing IBS using advanced microbiome and metabolite analysis coinciding with IBS Awareness Month in April.
Irritable Bowel Syndrome (IBS) is one of the most common yet underdiagnosed gastrointestinal disorders in India, affecting an estimated 4–8% of the population, or nearly 40–80 million people. IBS lacks a definitive test; most cases are identified based on commonly occurring symptoms like abdominal pain, cramping, bloating, and altered bowel habits, such as diarrhea, constipation, or both. This often leads to delays, misdiagnosis, and prolonged patient discomfort. Additionally, only a small proportion of individuals seek medical care, contributing to a significant hidden disease burden.
MicrobioTx’s IBS Risk Score leverages a combination of gut microbiome profiling and metabolite analysis biological signals released by microbes into the bloodstream to provide deeper insights into gut health. By analyzing these markers, the solution helps identify patterns associated with IBS, enabling early risk detection and more informed clinical decision-making.
MicrobioTx’s latest innovation aims to shift the approach from reactive diagnosis to proactive risk assessment. The offering builds on the company’s ongoing research in microbiome science and its recently concluded clinical study in collaboration with Maulana Azad Medical College, validated the high accuracy of its Gut Function Test (GFT) for Indian IBS patients. The study demonstrated strong predictive capabilities in identifying both general and IBS-specific microbiome imbalances.
“IBS is a prevalent and underdiagnosed condition. Gut dysbiosis is an important contributing factor in its development and is a potential therapeutic opportunity,” said. Dr Ujjwal Sonika, Professor, Gastroenterology, Maulana Azad Medical College and principal investigator for the study.
The data from the study is also used to build and launch an IBS Risk indicator that analyzes an individual’s microbiome and metabolic profile to help clinicians see if the gut profile of a person resembles metabolites and microbiome imbalance associated with IBS and hence help assess their IBS disease risk. The launch reinforces MicrobioTx’s commitment to building accessible, science-backed microbiome solutions. The company continues to focus on delivering affordable and clinically relevant innovations to advance the field of gut health and improve patient outcomes
